STAAR Surgical Company (STAA)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-14
$23.07+1.81%
Close 2026-09-14 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-14
Research Workspace
Put STAA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 43% in its worst 12-month stretch.
View RiskSTAAR Surgical's growth in China has to keep compounding to justify the price. Revenue jumped 111% year over year to $93.5 million, with a recent earnings beat. It trades at 29× P/E versus a peer median of 28×, indicating modest expectations compared to our view. If STAA cuts guidance on the next call, that could negatively impact the stock. Peer multiples imply a price about 12% above where it trades. This read is provisional.
Trailing returns as of 2026-09-14. STAA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering STAA (as of Sep 2026).
Based on 3 Wall Street analysts offering 12-month price targets for STAA in the last 4 months.
Continue this research
Compare STAA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| STAA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 7 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put STAA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Accelerate revenue growth in key markets
Profitability from China supports revenue growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $23.07
The last 12 months of price, then the range of analyst 12-month targets from today’s $23.07.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Accelerate revenue growth in key markets
Q2 profit rebound supports revenue growth objective.
Advances: Accelerate revenue growth in key markets
Record revenue surge supports growth in key markets.
Advances: Maintain disciplined capital allocation and cost management
Cash position supports disciplined capital allocation strategy.
Advances: Accelerate revenue growth in key markets
Q2 2026 revenue exceeds expectations, supporting growth objectives.
Advances: Increase revenue growth
Strong Q1 indicates revenue growth potential.
Advances: Increase revenue growth
Alcon overhang fading supports revenue growth.
Advances: Increase revenue growth
Durable turnaround signals sustained revenue growth.